GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

rosnilimab   Click here for help

GtoPdb Ligand ID: 14271

Synonyms: ANB-030 | ANB030
Immunopharmacology Ligand
Compound class: Antibody
Comment: Rosnilimab (ANB-030; AnaptysBio) is a programmed cell death 1 (PD-1) monoclonal antibody that activates the PD-1 signaling pathway as a mechanism to suppress pathogenic T cell-mediated immune activation for the treatment of autoimmune disorders [1,3-4]. PD-1 agonist monoclonals are claimed in AnaptysBio patent US20220235132 [2]. Peptide sequences for 3.7C6 (APE12095) clones in this patent match the complementarity-determining region (CDR) sequences that form the antigen-binding site of rosnilimab, as annotated by IMGT.
Click here for help
Bioactivity Comments
The biological data curated here is derived from clones 3.7C6 (APE12095) in the AnaptysBio patent [2].
Selectivity at other protein targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
programmed cell death 1 (CD279) Hs Antibody Agonist 10.3 pKd - 2
pKd 10.3 (Kd 5.1x10-11 M) [2]
Description: Binding affinity determined by SPR
programmed cell death 1 (CD279) Monkey Antibody Agonist 6.6 pKd - 2
pKd 6.6 (Kd 2.44x10-7 M) [2]
Description: Binding affinity determined by SPR
programmed cell death 1 (CD279) Hs Antibody Agonist ~6.3 pIC50 - 2
pIC50 ~6.3 (IC50 ~5x10-7 M) [2]
Description: Potency determined in a competition binding assay displacing human PD-L1